Abbott reported third-quarter 2026 results on October 21, 2026, with net sales up 14.5% to $13.0 billion, aided by the Exact Sciences acquisition completed March 23, 2026. GAAP diluted EPS fell 43.6% to $0.53 after specified items, including about $670 million of legal settlements and $841 million of intangible amortization, while adjusted diluted EPS rose 9.2% to $1.42. The company tightened its full-year 2026 adjusted EPS guidance to $5.50 to $5.55, reaffirming the midpoint, which matters to shareholders because reported profit fell sharply even as sales and adjusted earnings grew.
Third-quarter net sales were $13,013 million, up 14.5% reported and 7.0% on a comparable basis.
GAAP diluted EPS was $0.53, down from $0.94 a year earlier; adjusted diluted EPS was $1.42, up from $1.30.
Specified items included about $670 million in legal settlements and $841 million in intangible amortization.
Full-year 2026 adjusted diluted EPS guidance was narrowed to $5.50 to $5.55, with the midpoint reaffirmed; projected comparable sales growth is approximately 6.0%.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Abbott Laboratories's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$44.33B
+5.7%
$3.72
-51.3%
14.7%
FY2024
$41.95B
+4.6%
$7.64
+134.4%
31.9%
FY2023
$40.11B
-8.1%
$3.26
-16.6%
14.3%
FY2022
$43.65B
+1.3%
$3.91
-0.8%
15.9%
FY2021
$43.08B
+24.5%
$3.94
+57.6%
16.4%
Frequently asked questions
When is Abbott Laboratories's next earnings date?
Abbott Laboratories has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Abbott Laboratories earn last quarter?
For the quarter ended Sep 2026, Abbott Laboratories reported diluted EPS of $0.53 (-43.6% year over year) on revenue of $13.01B (+14.5%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.